News articles about Sequenom (NASDAQ:SQNM) have been trending positive recently, according to AlphaOne Sentiment. AlphaOne, a unit of Accern, identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real time. AlphaOne ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Sequenom earned a coverage optimism score of 0.26 on AlphaOne’s scale. AlphaOne also gave media stories about the biotechnology company an impact score of 84 out of 100, meaning that recent press coverage is very likely to have an effect on the company’s share price in the near term.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/05/01/sequenom-sqnm-given-media-impact-rating-of-0-26.html.

Sequenom Company Profile

Sequenom, Inc is a life sciences company. The Company serves patients and physicians by providing early patient management information. The Company operates through Sequenom Laboratories segment. It conducts its business as a molecular diagnostics clinical laboratory located in San Diego, California and Raleigh-Durham, North Carolina.

5 Day Chart for NASDAQ:SQNM

Receive News & Ratings for Sequenom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sequenom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.